Strong MIA, MIA2, and TANGO immunoreactivity levels were detected in 41% (43/105), 37.1% (39/105), and 40% (42/105) of SCCs, respectively; notably, the MIA, MIA2, and TANGO expression frequencies in adenocarcinomas, small cell carcinomas, and LCNECs were significantly lower than those in SCCs (Figure 3A–3F; P = 0.0307, P = 0.0453, and P = 0.0173, respectively). This evidence concerns the gene MIA2 and adenocarcinoma.